| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H21N3OS |
| Molecular Weight | 399.508 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1=NC(=C(S1)C2=CC(NC(=O)C3=CC=CC=C3)=NC=C2)C4=CC=CC(C)=C4
InChI
InChIKey=HEKAIDKUDLCBRU-UHFFFAOYSA-N
InChI=1S/C24H21N3OS/c1-3-21-27-22(18-11-7-8-16(2)14-18)23(29-21)19-12-13-25-20(15-19)26-24(28)17-9-5-4-6-10-17/h4-15H,3H2,1-2H3,(H,25,26,28)
| Molecular Formula | C24H21N3OS |
| Molecular Weight | 399.508 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
TAK 715 is an orally bioavailable drug, which was developed by Takeda as Anti-inflammatory and anti-rheumatoid arthritis agent. This drug was in phase II of clinical trials, but that study was discontinued. TAK 715 is an inhibitor of p38 MAPK alpha and is inhibitor of Wnt-3a-stimulated β-catenin signaling.
Originator
Approval Year
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
PubMed
Patents
Sample Use Guides
TAK-715 25 mg, 50 mg and 100 mg tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
Route of Administration:
Oral
It was synthesized a novel compound and evaluated it inhibition of p38 MAP kinase, lipopolysaccharide (LPS)-stimulated release of tumor necrosis factor-alpha (TNF-alpha) from human monocytic THP-1 cells in vitro. It was discovered, that TAK-715 exhibited potent inhibitory activity in these assays (inhibition of p38alpha, IC50 = 7.1 nM; LPS-stimulated release of TNF-alpha from THP-1, IC50 = 48 nM) and no inhibitory activity for major CYPs, including CYP3A4.
